Background and Aims: An expanding number of monogenic defects have been identified as causative of severe forms of very early-onset inflammatory bowel diseases [VEO-IBD]. The present study aimed at defining how next-generation sequencing [NGS] methods can be used to improve identification of known molecular diagnosis and to adapt treatment. Methods: A total of 207 children were recruited in 45 paediatric centres through an international collaborative network [ESPGHAN GENIUS working group] with a clinical presentation of severe VEO-IBD [n = 185] or an anamnesis suggestive of a monogenic disorder [n = 22]. Patients were divided at inclusion into three phenotypic subsets: predominantly small bowel inflammation, colitis 
with perianal lesions, and colitis only. Methods to obtain molecular diagnosis included functional tests followed by specific Sanger sequencing, custom-made targeted NGS, and in selected cases whole exome sequencing [WES] of parents-child trios. Genetic findings were validated clinically and/or functionally. Results: Molecular diagnosis was achieved in 66/207 children [32%]: 61% with small bowel inflammation, 39% with colitis and perianal lesions, and 18% with colitis only. Targeted NGS pinpointed gene mutations causative of atypical presentations, and identified large exonic copy number variations previously missed by WES. Conclusions: Our results lead us to propose an optimised diagnostic strategy to identify known monogenic causes of severe IBD.
Introduction
Very early-onset inflammatory bowel diseases [VEO-IBD] are defined by the development of chronic intestinal inflammation before the age of 6 years. A subgroup of patients suffer from a rapid and severe disease evolution, which raises difficult diagnostic and therapeutic issues. 1 In the latter patients, disease-causing mutations are identified in an increasing number of genes expressed in haematopoietic immune cells, in epithelial cells, or in both. Early molecular diagnosis is crucial in order to reduce mortality and morbidity, notably by defining whether haematopoietic stem cell transplantation [HSCT] is indicated.
Molecular diagnosis in VEO-IBD patients is classically based on precise phenotyping followed by selected functional tests and Sanger sequencing of candidate genes. 2, 3 Onset of severe bloody diarrhoea and perianal lesions a few weeks after birth suggests the existence of mutations inactivating the interleukin 10 [IL-10] receptor or IL10, [4] [5] [6] [7] whereas exudative diarrhoea in the context of autoimmunity-and notably type I diabetes-is highly suggestive of IPEX syndrome [Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked] due to mutations in Forkhead box P3 [FOXP3] gene. 8 However, such approach to molecular diagnosis has limitations given the increasing number of genes in which mutations have been identified and given recurrent evidence of lack of strict phenotypegenotype correlations. 9 Furthermore, in patients with overlapping clinical presentations, different pathophysiological defects require distinct therapeutic approaches. 10 Therefore, precise molecular diagnosis is a prerequisite for offering these patients access to optimal care with the best possible outcome.
These issues stress the need to establish time-and cost-effective clinical diagnostic protocols. 3, 11 Next-generation DNA sequencing [NGS] methods allow efficient genotype-based diagnosis. Whole genome [WGS] and whole exome [WES] sequencing provide unbiased approaches, but they remain relatively expensive, and can raise difficult challenges for analysis and interpretation, which limits their use for diagnostic purposes. Targeted NGS [TNGS] -also called targeted gene panel sequencing-emerges as a powerful tool for fast and simple screening of genes of interest. Since 2014, TNGS was proven to be valuable in the identification of primary immunodeficiencies, notably in patients with atypical presentations. 9, 12, 13 More recently, TNGS could identify causative mutations in small cohorts of VEO-IBD patients. 1, 14 The present study aimed at defining how next-generation sequencing [NGS] methods can be used to improve identification of known molecular defects and to adapt treatment accordingly. Based on our results, we propose an optimised diagnostic strategy to identify known monogenic causes of severe IBD depending on the phenotype of the patients. 15 Some genes of common variable immunodeficiency were included as well, as they can lead to severe intestinal inflammation. [16] [17] [18] [19] [20] [21] [22] Genes of severe combined immunodeficiencies, in which diarrhoea is usual but with a different clinical context, and genes associated with diseases with very specific and primarily extraintestinal symptoms such as bullous skin diseases or albinism, were excluded as affected patients are unlikely to be diagnosed in paediatric gastroenterology centres.
Methods

Patients
Genomic DNA libraries were generated from DNA [ 
Gene validation
All mutations identified by WES or TNGS, and not previously described as disease-causing in the literature, were validated as follows.
Novel mutations in SKIV2L and TTC37 were confirmed by reassessment of the clinical phenotype. The patients presented the canonical signs of syndromic diarrhoea within a tricho-hepatoenteric syndrome 32 : congenital diarrhoea [4/4] 
Results
Description of the cohort
Between August 2009 and August 2015, 207 consecutive patients with severe chronic diarrhoea were recruited; 144 patients had started their disease before the age of 2 years [70%] and 22 patients after the age of 6 years [ Table 1 ]. As described in Methods, and shown in Table 2 , patients were divided into three groups based on phenotype: 51 patients with small bowel inflammation and autoimmune features; 33 with colitis and perianal lesions; and 123 with colitis only. As shown in Figure 1 , 160 patients benefited from functional tests that were orientated by the clinical presentation: numbers and phenotype of regulatory T cells were determined in patients with small bowel inflammation, and signalling downstream IL-10 receptor or XIAP was assessed in patients with colitis with or without perianal lesions. In 32 patients with abnormal results, Sanger sequencing was used to confirm mutations in FOXP3, IL2RA, IL10RA, IL10RB 
Yield of molecular diagnoses according to the clinical phenotype
By combining selected functional tests and next-generation sequencing, approximately 30% of all the patients included in the present cohort received a molecular diagnosis. Yet, as mentioned above, clinical presentation differed between patients and functional tests were only available to validate a few gene defects. To optimise diagnostic work-up, we then analysed whether the frequency of identified molecular defects differed between the three groups of patients and, within each group of patients, when and how functional testing and TNGS had been most useful for diagnosis [ 34 a homozygous LRBA mutation in two other siblings, 37 a de novo gain-of-function mutation of STAT3 in one girl, and a homozygous MYO5B mutation in one boy in whom marked intestinal inflammation had erroneously led to ascribe the severe diarrhoea to an immune-mediated process. Mutations identified by TNGS included FOXP3 mutations in four boys, for three of whom only DNA was available and in one case normal number and phenotype of regulatory T cells but with abnormal suppressive function; a homozygous NEUROG3 mutation in one boy with chronic diarrhoea since the first months of life and type 1 diabetes since the age of one 38 ; compound heterozygous LRBA mutations in three patients, one boy with two missense mutation, and two siblings with one missense mutation and a large deletion [from exon 3 to exon 48]. As indicated above, this large deletion in LRBA had been missed by WES performed before TNGS.
The group with colitis and perianal lesions included 33 patients of whom 73% were boys. Among the 33 patients, 13 [19] IL10RA
List of genes and number of patients for each gene in brackets. WES, whole exome sequencing; TNGS, targeted next-generation sequencing.
IL-10 or XIAP signalling, all patients except one benefited from functional tests. 6, 36 Overall, diagnosis was oriented in 12 patients by functional tests, which showed either lack of responsiveness of peripheral monocytes to the inhibitory effect of exogenous IL-10 [n = 9] or lack of stimulation of the NOD2-XIAP pathway by muramyl-dipeptide [n = 3]. Sanger sequencing confirmed mutations in IL10RA [n = 3], IL10RB [n = 6], or XIAP [n = 3]. In one patient for whom only DNA was available, TNGS identified a homozygous IL10RA mutation.
The group of patients with only colitis comprised 123 patients of whom 59% were male. As defined above, they displayed neither autoimmune symptoms nor perianal lesions. [n = 1], and XIAP in four patients: in three boys for whom only DNA was available and in a 17-year-old girl with severe and refractory VEO-IBD since the age of 6 months. Because of X-linked inheritance, XIAP deficiency had not been considered. Following identification of a premature stop codon by TNGS, abnormal signalling downstream XIAP and reduced protein expression in 50% of PBMC were demonstrated. The same mutation was found in her sister, who had also developed very severe IBD. Of note, in three additional patients, rare variants identified by TNGS were ruled out, either because they were incompatible with the clinical phenotype [a rare heterozygous variant in PLCG2 was highly unlikely to be causative since the patient did not display any auto-inflammatory symptoms] or through functional testing [two variants in MYO5B in a patient with normal PAS staining of duodenal sections; two rare variants in IL21R but normal STAT3 phosphorylation of PBMC in response to IL-21].
Yield of molecular diagnoses depending on age at disease onset
As mentioned above, diagnostic yield on the whole cohort was 32%; 70% of the patients started their disease before the age of two years [144/207, Table 1 ]. Among the latter patients, diagnostic yield was slightly higher [41%] . Further analysis shows that, in patients with small bowel inflammation or colitis with perianal lesions, the vast majority of molecular diagnoses were identified in children with disease onset before the age of two years. In patients included despite later age at disease onset [n = 22], a monogenic defect was identified in four cases [18%].
Discussion
An expanding number of monogenic defects have been identified as causative of severe forms of VEO-IBD. These diseases are individually rare but, collectively, they raise difficult diagnostic and therapeutic issues due to their severity and considerable genetic heterogeneity. Paediatric gastroenterologists from ESPGHAN created the GENIUS working group in 2009 with the goals of fostering clinical knowledge of these diseases and facilitating development of therapeutic strategies based on precise molecular diagnosis. The resulting cooperation between 45 paediatric centres allowed us to comprehensively investigate the potential monogenic causes of severe VEO-IBD and to propose guidelines for the diagnosis of known molecular defects.
The 207 patients described in this study represent the largest European cohort to date. Overall, 32% of patients obtained a molecular diagnosis. Diagnosis yield, however, varied when patients were stratified by their phenotypes. Molecular diagnosis was obtained in two-thirds of children presenting with small bowel inflammation suggestive of 'IPEX' syndrome, and in almost half of patients having colitis with severe perianal lesions. In contrast, diagnosis yield in the 'Colitis only' subset was relatively low [less than 20%]. These differences remain to be explained. A possible hypothesis is that not all cases of early-onset colitis have a monogenic cause, notably in patients with disease onset beyond the first 2 years of life and in absence of familial history.
In LRBA (2) MALT1 (2) IL2R (2) IL10RA (2) XIAP (6) IL10RB (7) FOXP3 ( Of note, a molecular diagnosis was identified in four out of 22 patients who had started their disease after 6 years. These four patients [with defects in LRBA, NCF1, and XIAP] would have remained undiagnosed with a cut-off for inclusion at 6 years. Given increasing evidence of de novo mutations, of incomplete penetrance, and of delayed disease onset in patients with mutations in notably XIAP, CTLA4, LRBA, STAT3, or NLRC4, [17] [18] [19] [20] [21] [22] 36, 37, 39 we thus recommend that access to TNGS screening should be considered not only in all severe VEO-IBD patients, but also in older children or teenagers with very severe intestinal diseases refractory to medical treatment. The modest cost per patient renders this option economically affordable and may prove instrumental to guide therapeutic strategy. This is exemplified in our cohort by a case of XIAP deficiency diagnosed in a young adult, who had already undergone colectomy, thus too late to propose treating the colitis by HSCT. 40 Based on the retrospective analysis of this large multicentre cohort of severe VEO-IBD patients, we propose an algorithm to obtain a molecular diagnosis in an optimised manner [ Figure 2 ]. It has to be validated prospectively in an independent cohort of patients. In addition to severe chronic diarrhoea starting early in life, some atypical clinical features may orientate towards specific monogenic defects [hair abnormalities, dysmorphia, autoimmunity, eczema, allergy, immune deficiency, etc]. Combined with laboratory tests and endoscopic and histology findings, this precise phenotyping allows division of patients into three groups as described above. Since many monogenic forms of VEO-IBD are primary immunodeficiencies, standard immunological work-up is recommended [see Figure 2 ]. When pathognomonic symptom associations evoke a specific monogenic disorder, corresponding functional tests should be considered as they may quickly orientate molecular diagnosis within only a few days.
When functional tests fail to orientate toward a molecular defect, NGS methods need to be considered, given the genetic heterogeneity and important phenotype-genotype overlaps. TNGS, WES, and WGS are non-hypothesis driven assays that allow molecular diagnosis in patients with atypical clinical presentations. In a routine clinical setting, TNGS is the method to prefer as it is cost-and time-effective while providing optimal coverage of the genes of interest [see Supplementary Table 2 , available as Supplementary data, available at ECCO-JCC online]. Regularly updating the panel of genes to be targeted upon identification of novel disease-causing genes should progressively increase sensitivity and diagnostic yield. WES could be performed as a second-line genetic assay when TNGS has failed to reveal a molecular diagnosis. WES-and furthermore WGS-will allow identification of novel causative genes, but they require an 
